CBA-1205
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for CBA-1205, covering 2025-09-19 to 2025-09-19. Get the full timeline:
Most recent: Clinical Trial Update: A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer [Phase 1]